ADMA Biologics, Inc.
ADMA Biologics, Inc. (ADMA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
adma · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for ADMA Biologics, Inc. (ADMA) measures how much investors pay for each dollar of the company's trailing earnings. ADMA's current PE ratio of 11.53x is calculated by dividing its stock price of $8.09 by its TTM earnings per share of $0.70. −53.7% discount vs 5Y avg 24.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
ADMA Biologics, Inc.You ADMA | $1.9B | 11.53x | -43.7% | $0.70 |
 ACADIA Pharmaceuticals Inc. ACAD | $3.7B | 11.57x | -43.5% | $2.31 |
 Belite Bio, Inc BLTE | $5.6B | N/A | — | -$2.31 |
 Crinetics Pharmaceuticals, Inc. CRNX | $3.5B | N/A | — | -$4.95 |
 Dyne Therapeutics, Inc. DYN | $2.8B | N/A | — | -$3.47 |
 Ligand Pharmaceuticals Incorporated LGND | $4.8B | 29.38x | +43.5% | $6.44 |
 Mirum Pharmaceuticals, Inc. MIRM | $4.7B | N/A | — | -$0.47 |
Industry Average 2 peers with valid PE | — | 20.47x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 29.58x | $0.62 | +46.3% | |
2024-12-31 FY2024 | 20.22x | $0.85 | — | |
2023-12-31 FY2023 | — | $-0.13 | — | |
2022-12-31 FY2022 | — | $-0.33 | — | |
2021-12-31 FY2021 | — | $-0.51 | — | |
2020-12-31 FY2020 | — | $-0.88 | — | |
2019-12-31 FY2019 | — | $-0.89 | — | |
2018-12-31 FY2018 | — | $-1.45 | — | |
2017-12-31 FY2017 | — | $-1.91 | — | |
2016-12-31 FY2016 | — | $-1.61 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for ADMA Biologics, Inc. (ADMA) measures how much investors pay for each dollar of the company's trailing earnings. ADMA's current PE ratio of 11.53x is calculated by dividing its stock price of $8.09 by its TTM earnings per share of $0.70.
Frequently asked questions
ADMA pe ratio · 6 questionsADMA's current PE ratio is 11.53x as of 2026-06-08, based on a stock price of $8.09 and TTM EPS of $0.70. Data sourced from Financial Modeling Prep via ADMA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · ADMA Biologics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08